Everything we know so far about BBV154-Technology News, Firstpost – California News Times

Barat Biotech has announced the results of the COVID-19 vaccine covaxin level 2 in India and is now experimenting with indoor vaccines in different parts of the country. According to the company, stage one tests will be conducted in Pana, Chennai, Hyderabad and Nagorno. BBV154, Tested to prevent CV-19 infection. If a person is infected, the vaccine is intended to prevent the development of COVID-19. It is later known that the COVID-19 vaccine, in combination with Bavarate Biotech, will be effective against covaxine. Covaxine has been shown to be 80.4% effective in preventing covad-19 infection.

Here’s what you need to know about this new type of vaccine when the trial begins

Barrat biotech nasal spray

Based in Hyderabad, Barat Biotech is working on the first intracellular vaccine for COVID-19 in India in collaboration with Precision Virologics, developed by the University of St. Louis in Washington, DC. The vaccine was developed by University of Washington professors David Curiel, a cancer biologist, and Michael Almaz, a viral pathologist. St. Louis Post Delivery Report..

The Phase One trial was conducted at the University of St. Louis Department of Immunization and Medical Assessment at the beginning of the United States. Following this, Barat Biotech will also conduct an investigation in India. If both tests give good results, Barat Biotech The vaccine is then produced. I bought the right to distribute Vaccines for all world markets except the United States, Japan and Europe.

Nasal administration has many benefits because it requires a much smaller dose than a vaccine.

More information on the techniques used and information from animal studies are published in the journal Cell, In the editorial with Nature..

The results show that BBV154 provides “an unprecedented level of protection in mouse studies.”

BBV154 Intranasal Vaccine

The most common way to distribute COVID-19 is through air. Or because of close contact, large drops or small drops called aerosol. The SARS-CoV-2 virus usually enters the body through the nose and body. Intravenous vaccines are given through the nose instead of through the skin. With this vaccine, the vaccine contains the virus in the nasal mucus, where there is a high risk of SARS-CoV-2 virus infection.

Nasal vaccines can be given by spraying, injection or injection without nasal drops The Age of India When given in the form of nasal drops, the vaccine blocks the virus in the area (nose) and stimulates the production of bacteria in the blood.

The Barrat Biotech Nasal Vaccination is an adenoviral vector vaccine made from the weakened version of the flu virus first presented by chimpanzees. Adjusted to target as a coronavirus. In addition to the covacid vaccine developed by the University of Ostrezenneka and the University of Oxford and produced by the Indian Serum Institute, Kovaxin is administered to India under the world’s largest vaccine drive.

as if Nature ReportDuring animal studies, rats with a single dose of nasal vaccine “have little to no protection against SARS-CoV-2 in the upper or lower respiratory tract.”

Vaccinated rats, on the other hand, were partially protected.

Nasal vaccines have many benefits over needles because they require a much smaller dose than a needle. St. Louis Post Report. Nasal vaccines are “easy to administer” because they involve spraying and little training. It is also useful for both children and adults who are afraid of needles.

Clinical trials in India

Indian Superintendent of Pharmaceuticals, Indian Pharmacist General (CDC), Approved Level 1 and Level 2 experiments with nasal vaccines planned last month by Barat Biotech. The CDSCO recommends that companies generate 75 safety volunteer information from the level 1 I have reached. That other reports cite high numbers – 150175 – Level 1 research volunteers.

“Candidate for nasal vaccine has been identified. It is currently being considered in Phase 1 and Level 2 experiments. If it works, it could be a game changer, ”said Nitty-Yog, a member of Nitty Glass. ) Says VK Paul. They said India Express..

Forty-two days after the administration of nasal sprays, a temporary analysis of the results is performed. To participate in the immunization test, volunteers must be healthy adults who are not infected with COVID-19.

According to sources, trials have already begun in hospitals in Hyderabad, Nagornog, Patna and Chennai. Hindu trade line.

Four countries around the world are working on different types of vaccines.

Other nasal vaccines are under construction

Three other countries around the world are also testing intravenous vaccines. In addition to India, US companies are also testing. Altimumun We are preparing a nasal spray called Adcovid. He says the vaccine is especially effective in preventing covad-19 infection in children. The experiment was started by a group of 180 volunteers aged 18-55.

In England Codegenics The nasal vaccine COVI-VAC has been introduced in stage 1 clinical trials by 48 volunteers. The vaccine detects not only the protein but also the whole virus. The vaccine is being developed in collaboration with the Indian Serum Institute.

She has not given up, and China is also working on the Iranian vaccine. Beijing Wang Tai Thai Biological Pharmacy Enterprise is working with Xiamen University and the University of Hong Kong. Phase 1 trials of this vaccine have been approved and will begin in November 2020. Intranasil contains weakened influenza viruses such as H1N1, H3N22 and B. Level 1 enrolled 100 volunteers and is expected to take one year to complete.

Editor’s note: This article was first published on March 12, 2021, when Bahara Biotech launched domestic immunization tests. On August 1, a team of experts from the Central Pharmaceutical Authority of India, Barat Biotech, proposed a study on the compatibility of covassin with BBV154, a nasal vaccine candidate under study.

So far we know about BBV154-Technology News, Firstpost Source Link All we know about BBV154-Technology News, Firstpost

Leave a Comment